MX2014006182A - Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. - Google Patents
Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.Info
- Publication number
- MX2014006182A MX2014006182A MX2014006182A MX2014006182A MX2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr inhibitor
- treatment
- patient
- predicting responsiveness
- egfr
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 3
- 230000004043 responsiveness Effects 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306568 | 2011-11-25 | ||
| EP12306042 | 2012-08-31 | ||
| PCT/EP2012/073535 WO2013076282A1 (en) | 2011-11-25 | 2012-11-23 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014006182A true MX2014006182A (es) | 2014-12-08 |
Family
ID=47297187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006182A MX2014006182A (es) | 2011-11-25 | 2012-11-23 | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10400284B2 (OSRAM) |
| EP (1) | EP2783017B1 (OSRAM) |
| JP (1) | JP6342329B2 (OSRAM) |
| KR (1) | KR20140104419A (OSRAM) |
| CN (1) | CN104160038B (OSRAM) |
| AU (1) | AU2012342397B2 (OSRAM) |
| BR (1) | BR112014012495A2 (OSRAM) |
| CA (1) | CA2856594A1 (OSRAM) |
| MX (1) | MX2014006182A (OSRAM) |
| WO (1) | WO2013076282A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105765081A (zh) * | 2013-11-26 | 2016-07-13 | 英特盖根公司 | 一种用于预测对采用egfr抑制剂的治疗的响应性的方法 |
| KR101622454B1 (ko) | 2014-03-04 | 2016-05-18 | 연세대학교 산학협력단 | Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커 |
| WO2015160868A1 (en) * | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| EP3000895A1 (en) | 2014-09-26 | 2016-03-30 | Integragen | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| WO2017014694A1 (en) * | 2015-07-23 | 2017-01-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
| CN109072228A (zh) * | 2016-04-28 | 2018-12-21 | 电化株式会社 | 判定癌细胞对于表皮细胞生长因子受体抑制剂的耐性的方法 |
| EP3948274A1 (en) * | 2019-03-29 | 2022-02-09 | Rakuten Medical, Inc. | Methods for photoimmunotherapy and related biomarkers |
| KR102251864B1 (ko) * | 2019-10-18 | 2021-05-14 | 지니너스 주식회사 | miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물 |
| CN111798918A (zh) * | 2020-05-28 | 2020-10-20 | 中山大学孙逸仙纪念医院 | 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法 |
| CN111863159B (zh) * | 2020-06-01 | 2022-02-25 | 中山大学孙逸仙纪念医院 | 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法 |
| EP4486921A1 (en) * | 2022-03-01 | 2025-01-08 | Crown Bioscience (Suzhou) Inc. | Methods for determining cetuximab sensitivity in cancer patients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4808365B2 (ja) | 2001-03-02 | 2011-11-02 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｐｃｒ法 |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| WO2009080437A1 (en) * | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| WO2010121238A2 (en) | 2009-04-17 | 2010-10-21 | Translational Genomics Research Institute (Tgen) | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
| WO2011063456A1 (en) * | 2009-11-24 | 2011-06-03 | The University Of Western Australia | Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors |
| WO2011135459A2 (en) * | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
-
2012
- 2012-11-23 CN CN201280067832.4A patent/CN104160038B/zh not_active Expired - Fee Related
- 2012-11-23 EP EP12797814.6A patent/EP2783017B1/en not_active Not-in-force
- 2012-11-23 AU AU2012342397A patent/AU2012342397B2/en not_active Ceased
- 2012-11-23 US US14/360,311 patent/US10400284B2/en not_active Expired - Fee Related
- 2012-11-23 KR KR1020147014013A patent/KR20140104419A/ko not_active Ceased
- 2012-11-23 WO PCT/EP2012/073535 patent/WO2013076282A1/en not_active Ceased
- 2012-11-23 CA CA2856594A patent/CA2856594A1/en not_active Abandoned
- 2012-11-23 MX MX2014006182A patent/MX2014006182A/es unknown
- 2012-11-23 JP JP2014542865A patent/JP6342329B2/ja not_active Expired - Fee Related
- 2012-11-23 BR BR112014012495A patent/BR112014012495A2/pt active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| US20140370029A1 (en) | 2014-12-18 |
| WO2013076282A1 (en) | 2013-05-30 |
| BR112014012495A2 (pt) | 2017-06-06 |
| EP2783017B1 (en) | 2018-12-26 |
| CN104160038A (zh) | 2014-11-19 |
| EP2783017A1 (en) | 2014-10-01 |
| AU2012342397B2 (en) | 2018-04-05 |
| CN104160038B (zh) | 2018-06-12 |
| CA2856594A1 (en) | 2013-05-30 |
| JP6342329B2 (ja) | 2018-06-13 |
| AU2012342397A1 (en) | 2014-06-12 |
| US10400284B2 (en) | 2019-09-03 |
| JP2014533960A (ja) | 2014-12-18 |
| KR20140104419A (ko) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014006182A (es) | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. | |
| MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
| LTPA2019503I1 (lt) | Modifikuotų T ląstelių, turinčių chimerinų antigeno receptorių, panaudojimas vėžio gydymui | |
| MX2013014153A (es) | Biomarcadores paa terapia de inhibidor de hedgehog. | |
| IL233019A0 (en) | System and method for locating sources of biological arrhythmias | |
| EP2770090A4 (en) | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY AND USES THEREOF AND KITS THEREFOR | |
| EP2818108A4 (en) | METHOD FOR DETERMINING GLUCOSE CONCENTRATION IN HUMAN BLOOD | |
| IN2012DN02485A (OSRAM) | ||
| PT2683384E (pt) | Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| IN2014DN04645A (OSRAM) | ||
| WO2012106718A3 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
| EA201490265A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EP2788773A4 (en) | DEVICE, SYSTEM AND METHOD FOR IDENTIFYING CIRCULATING TUMOR CELLS | |
| WO2011146568A8 (en) | Predicting response to a her inhibitor | |
| WO2013040436A3 (en) | Esx-mediated transcription modulators and related methods | |
| EA201590773A1 (ru) | Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа) | |
| MX348655B (es) | Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer. | |
| MX354270B (es) | Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. . | |
| PH12013502530A1 (en) | Glioblastoma inhibiting compounds and their use | |
| EP2568459A4 (en) | TRAFFIC CONTROL SYSTEM AND METHOD | |
| IL232493A0 (en) | A method for quantifying cancer treatment | |
| PL2678443T3 (pl) | Sposób ilościowego określania ludzkiego DNA przy użyciu kontroli wewnętrznej | |
| GB201312965D0 (en) | Stem cell factor inhibitor | |
| EA201500670A1 (ru) | Egfr-направленная терапия неврологических нарушений и боли |